IQVIA Holdings Inc. $IQV Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,374,971 shares of the medical research company’s stock after acquiring an additional 24,453 shares during the period. Geode Capital Management LLC’s holdings in IQVIA were worth $982,272,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Eubel Brady & Suttman Asset Management Inc. acquired a new stake in shares of IQVIA in the 3rd quarter worth $14,278,000. Eagle Rock Investment Company LLC increased its stake in shares of IQVIA by 33.6% during the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares during the period. OPTIMAS CAPITAL Ltd purchased a new position in IQVIA during the third quarter worth about $4,008,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in IQVIA in the third quarter valued at about $7,368,000. Finally, AMG National Trust Bank purchased a new stake in IQVIA in the 3rd quarter valued at approximately $3,713,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IQV shares. Truist Financial cut their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. UBS Group reduced their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Stock Performance

Shares of IQV stock opened at $182.03 on Friday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market cap of $30.38 billion, a PE ratio of 22.56, a P/E/G ratio of 1.73 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $136.41 and a 1 year high of $247.04. The stock has a fifty day moving average price of $170.34 and a 200 day moving average price of $196.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the company posted $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.